Journal Article

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Raje, Noopur, Laribi, Kamel, Shimizu, Kazuyuki, Durie, Brian, Cheng, Paul, Roodman, G David, Terpos, Evangelos, Warner, Douglas, Legieć, Wojciech, Willenbacher, Wolfgang, Krejčí, Marta, Zhu, Li, García-Sanz, Ramón

2018

Overview

Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone). Denosumab, a monoclonal antibody targeting RANKL, reduces skeletal-related events associated with bone lesions or metastases in patients with advanced solid tumours. This study aimed to assess the efficacy and safety of denosumab compared with zoledronic acid for the prevention of skeletal-related events in patients with newly diagnosed multiple myeloma. In this international, double-blind, double-dummy, randomised, active-controlled, phase 3 study, patients in 259 centres and 29 countries aged 18 years or older with symptomatic newly diagnosed multiple myeloma who had at least one documented lytic bone lesion were randomly assigned (1:1; centrally, by interactive voice response system using a fixed stratified permuted block randomisation list with a block size of four) to subcutaneous denosumab 120 mg plus intravenous placebo every 4 weeks or intravenous zoledronic acid 4 mg plus subcutaneous placebo every 4 weeks (both groups also received investigators' choice of first-line antimyeloma therapy). Stratification was by intent to undergo autologous transplantation, antimyeloma therapy, International Staging System stage, previous skeletal-related events, and region. The clinical study team and patients were masked to treatment assignments. The primary endpoint was non-inferiority of denosumab to zoledronic acid with respect to time to first skeletal-related event in the full analysis set (all randomly assigned patients). All safety endpoints were analysed in the safety analysis set, which includes all randomly assigned patients who received at least one dose of active study drug. This study is registered with ClinicalTrials.gov, number NCT01345019. From May 17, 2012, to March 29, 2016, we enrolled 1718 patients and randomly assigned 859 to each treatment group. The study met the primary endpoint; denosumab was non-inferior to zoledronic acid for time to first skeletal-related event (hazard ratio 0·98, 95% CI 0·85–1·14; pnon-inferiority=0·010). 1702 patients received at least one dose of the investigational drug and were included in the safety analysis (850 patients receiving denosumab and 852 receiving zoledronic acid). The most common grade 3 or worse treatment-emergent adverse events for denosumab and zoledronic acid were neutropenia (126 [15%] vs 125 [15%]), thrombocytopenia (120 [14%] vs 103 [12%]), anaemia (100 [12%] vs 85 [10%]), febrile neutropenia (96 [11%] vs 87 [10%]), and pneumonia (65 [8%] vs 70 [8%]). Renal toxicity was reported in 85 (10%) patients in the denosumab group versus 146 (17%) in the zoledronic acid group; hypocalcaemia adverse events were reported in 144 (17%) versus 106 (12%). Incidence of osteonecrosis of the jaw was not significantly different between the denosumab and zoledronic acid groups (35 [4%] vs 24 [3%]; p=0·147). The most common serious adverse event for both treatment groups was pneumonia (71 [8%] vs 69 [8%]). One patient in the zoledronic acid group died of cardiac arrest that was deemed treatment-related. In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic acid for time to skeletal-related events. The results from this study suggest denosumab could be an additional option for the standard of care for patients with multiple myeloma with bone disease. Amgen.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Acids / Adverse events / Aged / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Apoptosis / Autografts / Bisphosphonates / Bone Density Conservation Agents - adverse effects / Bone Density Conservation Agents - therapeutic use / Bone diseases / Bone lesions / Bone marrow / Bone Neoplasms - complications / Bone Neoplasms - mortality / Bone Neoplasms - prevention & control / Bone Neoplasms - secondary / Bone surgery / Cancer therapies / Clinical trials / Compression / Cytokines / Denosumab - adverse effects / Denosumab - therapeutic use / Disease prevention / Double-Blind Method / Double-blind studies / Drug dosages / FDA approval / Female / Fractures, Spontaneous - etiology / Fractures, Spontaneous - mortality / Fractures, Spontaneous - pathology / Fractures, Spontaneous - prevention & control / Hematology, Oncology, and Palliative Medicine / Humans / Hypercalcemia / Hypocalcemia / Immunotherapy / Intravenous administration / Jaw / Male / Medical prognosis / Metastases / Middle Aged / Monoclonal antibodies / Mortality / Multiple myeloma / Multiple Myeloma - complications / Multiple Myeloma - drug therapy / Multiple Myeloma - mortality / Multiple Myeloma - pathology / Neutropenia / Osteolysis / Osteonecrosis / Patients / Placebos / Plasma / Pneumonia / Progression-Free Survival / Quality of life / Radiation therapy / Risk Factors / Safety / Solid tumors / Spinal cord / Spinal Cord Compression - etiology / Spinal Cord Compression - mortality / Spinal Cord Compression - pathology / Spinal Cord Compression - prevention & control / Survival analysis / Targeted cancer therapy / Thrombocytopenia / Time Factors / Toxicity / TRANCE protein / Transplantation / Treatment Outcome / Zoledronic acid / Zoledronic Acid - adverse effects / Zoledronic Acid - therapeutic use